4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found
      Is Open Access

      Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The ODYSSEY COMBO I study (http://clinicaltrials.gov/show/NCT01644175) evaluated efficacy and safety of alirocumab as add-on therapy to stable maximally tolerated daily statin with or without other lipid-lowering therapy in high cardiovascular risk patients with suboptimally controlled hypercholesterolemia.

          Related collections

          Author and article information

          Journal
          Am. Heart J.
          American heart journal
          1097-6744
          0002-8703
          Jun 2015
          : 169
          : 6
          Affiliations
          [1 ] The Christ Hospital, Heart and Vascular Center/The Lindner Research Center, Cincinnati, OH. Electronic address: Lindner@thechristhospital.com.
          [2 ] University of Iowa, Iowa City, IA.
          [3 ] Harvard Clinical Research Institute, Boston, MA.
          [4 ] Sanofi, Chilly-Mazarin, France.
          [5 ] Regeneron Pharmaceuticals, Inc, Tarrytown, NY.
          [6 ] Sanofi, Bridgewater, NJ.
          [7 ] University of Dundee, Dundee, Scotland, United Kingdom.
          Article
          S0002-8703(15)00168-4
          10.1016/j.ahj.2015.03.004
          26027630
          f9c256ed-2a82-4056-b199-9a2ab109a765
          Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

          Comments

          Comment on this article